These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 12082955)

  • 1. [The LIFE study: extensive marketing in Denmark. Suggestions to conclusions based on the study].
    Lindberg M
    Lakartidningen; 2002 May; 99(20):2324. PubMed ID: 12082955
    [No Abstract]   [Full Text] [Related]  

  • 2. [Marketing of the LIFE trial anticipates evaluation of the drug].
    Järhult B
    Lakartidningen; 2002 Apr; 99(17):1964. PubMed ID: 12043424
    [No Abstract]   [Full Text] [Related]  

  • 3. [Marketing of researchers--lack of judgment or a new trend?].
    Werkö L; Hernborg A; Liedholm H; Melander A
    Lakartidningen; 2002 Apr; 99(17):1962-3. PubMed ID: 12043423
    [No Abstract]   [Full Text] [Related]  

  • 4. [An announcement from the ALLHAT: Thiazide diuretics are medically and economically superior].
    Lindblad U; Melander A
    Lakartidningen; 2003 Feb; 100(6):413-4. PubMed ID: 12607433
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Keiding H; Hildebrandt P; Burke T; Carides GW
    Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tax payers have payed billions for the "blood pressure maffia's" actions].
    Järhult B; Lindahl SO
    Lakartidningen; 2003 May; 100(21):1917-8. PubMed ID: 12815880
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Three comments on the LIFE trial].
    Rastad JA
    Lakartidningen; 2002 May; 99(18):2090. PubMed ID: 12082791
    [No Abstract]   [Full Text] [Related]  

  • 9. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
    J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reply 2: nonchalant and fabricated criticism].
    Lindberg G; Melander A
    Lakartidningen; 2000 Sep; 97(39):4348. PubMed ID: 11076481
    [No Abstract]   [Full Text] [Related]  

  • 11. [Real and assumed potential savings in antihypertensive treatment. Right out of the magician's hat].
    Anlauf M; Hense HW
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1557-9. PubMed ID: 12854069
    [No Abstract]   [Full Text] [Related]  

  • 12. [Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
    Traut
    Dtsch Med Wochenschr; 2003 Jan; 128(4):161; discussion 161-2. PubMed ID: 12589590
    [No Abstract]   [Full Text] [Related]  

  • 13. Improving prescribing practices in primary care. A randomised trial and economic analysis of a multicomponent intervention showed small, but important, gains.
    Del Mar C
    PLoS Med; 2006 Jun; 3(6):e229. PubMed ID: 16729845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fixed-combination of losartan/hydrochlorothiazide 100 mg/25 mg. Tolerability and efficacy on blood pressure measured in the practice and for 24 hours].
    Förster A; Smolka W; Jung C; Bestehorn K
    MMW Fortschr Med; 2007 Sep; 149(35-36):38. PubMed ID: 17944283
    [No Abstract]   [Full Text] [Related]  

  • 15. [LIFE study proves preventive action. With losartan to do even more against stroke].
    Baumgart P
    MMW Fortschr Med; 2003; 145 Suppl 1():7-8. PubMed ID: 12958796
    [No Abstract]   [Full Text] [Related]  

  • 16. An economic evaluation of the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece.
    Stafilas PC; Sarafidis PA; Lasaridis AN; Aletras VH; Niakas DA
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1233-40; discussion 1241-2. PubMed ID: 16182115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications.
    Robbiano L; Martelli A; Brambilla G
    J Hum Hypertens; 2005 Oct; 19(10):819-22. PubMed ID: 15951739
    [No Abstract]   [Full Text] [Related]  

  • 18. [Research and marketing].
    Meland E; Hernborg A
    Tidsskr Nor Laegeforen; 2004 Jul; 124(13-14):1820. PubMed ID: 15229677
    [No Abstract]   [Full Text] [Related]  

  • 19. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
    Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
    Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Uric acid--more deleterious than we thought?].
    Høieggen A; Os I; Kjeldsen SE
    Tidsskr Nor Laegeforen; 2005 May; 125(10):1330-2. PubMed ID: 15909004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.